Work

A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer

Year: 2004

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2004.22.14_suppl.4126

Authors: C. R. Becerra, C. Takimoto, J. A. Ajani, P. Major, K. Feit, A. Duggal, R. De Jagger

Institutions: The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2249762577

Cites:

Cited by: 2

Related to: 10